Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Markets

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 21, 2021 9:57am

176 Views

Post# 33247202

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Markets

Doccole wrote: From your talks with Dan-

do you think a chance of buyout has increased ? Or are we still looking at partnership?

Not from my talks with Dan but I would only guess that Big Pharma isn't prepared to spend the kind of money that we are looking to receive. We have to prove ourselves first.

My guess is that we're looking at large partnerships for OTENA - but - I'm sure things could change quickly. All depends where the talks go - if they see eye-to-eye or if the data convinces a Big Pharma that they need to act sooner than later.

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Cannabis Report – Nov. 15, 2024